TLDR: The artificial intelligence (AI) market in pharmaceutical and formulation chemistry is experiencing substantial growth, projected to reach $18 billion by 2033. Key industry players like AstraZeneca and Exscientia are leveraging AI to accelerate drug discovery, enhance precision medicine, and optimize R&D processes. This surge is driven by advancements in generative AI, increased investment, and the need for greater efficiency and speed in molecular innovation.
The integration of Artificial Intelligence (AI) into the pharmaceutical and formulation chemistry sectors is poised for a major expansion, with market projections indicating robust growth over the next decade. According to a recent study by HTF Market Intelligence, the global AI in pharmaceuticals market is anticipated to surge from $4.0 billion USD in 2025 to an impressive $18.0 billion USD by 2033, demonstrating a compound annual growth rate (CAGR) of 20.60%.
This significant market movement is being driven by a confluence of factors, including rapid digitalization, the convergence of AI with biotechnology, and a heightened focus on accelerating drug discovery and enhancing precision medicine. Major industry players, including AstraZeneca and Exscientia, are at the forefront of this transformation, leveraging AI to automate molecular screening, predict drug efficacy, and identify novel therapeutic targets. While Evotec was mentioned in initial reports, the broader market analysis highlights a wide array of companies actively shaping this landscape, such as IBM Watson Health, Pfizer, Novartis, Sanofi, Bayer, GlaxoSmithKline, Merck, BenevolentAI, and many others.
Key Trends and Advancements in 2025:
One of the most exciting trends is the widespread adoption of generative AI for designing novel molecules and proteins. This technology enables the creation of new molecular structures and significantly reduces R&D timelines and costs by accelerating lead identification. For instance, Merck’s AIDDISSON platform exemplifies how machine learning is being used to generate targeted drug candidates with unprecedented accuracy. In January 2025, scientists, utilizing AI, successfully developed a fluorescent protein, esmGFP, by simulating 500 million years of molecular evolution, an achievement published in Science that underscores AI’s capacity to not only mimic but also accelerate natural processes.
AI is also playing a crucial role in advancing CRISPR-based genome editing, with algorithms now assisting in identifying novel editing proteins, predicting off-target effects, and guiding safer therapeutic applications. This is particularly relevant following the first FDA-approved CRISPR therapy for sickle cell disease, a milestone partly attributed to AI’s guidance. The profound impact of AI on modern science was further validated in 2024 when Demis Hassabis, John Jumper, and David Baker received the Nobel Prize in Chemistry for their breakthroughs in protein structure prediction and AI-designed proteins.
Market Dynamics and Future Outlook:
The AI-native drug discovery market alone is projected to reach $1.7 billion in 2025, with forecasts estimating $7–8.3 billion by 2030, reflecting a CAGR exceeding 32%. The broader AI in chemicals market, encompassing materials and synthesis processes, is set to explode from $651 million in 2023 to over $10.3 billion by 2032, at a CAGR of 35.9%.
This acceleration is fueled by several factors: AI’s ability to reduce lead generation timelines by up to 28% and virtual screening costs by up to 40%, leading to leaner and faster pipelines. The maturity of data and infrastructure, coupled with increased investment and collaboration—evidenced by over $700 million in AI-biotech deals in 2024—are also critical drivers. Furthermore, AI contributes to sustainability mandates by optimizing energy-efficient reactions and identifying low-impact material alternatives, while evolving regulatory frameworks from bodies like the FDA and EMA are beginning to integrate AI into approval processes.
Also Read:
- Recursion Pharmaceuticals and NVIDIA Forge $50 Million Alliance to Advance AI-Driven Drug Discovery
- AI in Aviation Sector Set for Explosive Growth, Projected to Reach $36.3 Billion by 2035
Looking ahead, 2025 and the coming decade are expected to see the normalization of AI-native labs, where AI forms the fundamental basis of operations rather than merely being a tool. This paradigm shift will lead to greater utilization of AI in personalized and precision medicine, predictive toxicology, smart materials, bioengineered compounds, and closed-loop robotic experimentation. The industry is witnessing a molecular renaissance, where human ingenuity and machine intelligence collaborate to author the next chapter of scientific progress, ultimately accelerating solutions to pressing global health, climate, and industrial challenges.
